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Table 3. Comprehensive Summary Table on Literature Review of Onabotulinum Toxin A
Kuo	HC	(2012)
Taiwan
Prospective	
interventional	study
81	consecutive	patients	with	IC/PBS	who	failed	conventional	treatments	were	
prospectively	enrolled	in	this	study	from	July	2006	to	August	2010.	Patients	
were	requested	to	keep	a	bladder	diary	to	asses	frequency	and	nocturia.	
Baseline	scores	were	assessed	for	O'Leary	Sant	questionnaires	and	the	VAS	
responses.	Video-urodynamic	studies	and	pottasium	chloride	sensitivity	tests	
were	preformed.	Patients	with	GRA	>2	result	after	treatment	were	considered	
to	have	a	successful	treatment	outcome.	Patients	were	admitted	to	the	
hospital	for	treatment	where	they	received	intravesical	injection	of	botox,	
followed	by	cytoscopic	hydrodistention.	After	BoNT-A	injections,	a	catheter	
remained	for	1	day	and	patients	were	discharged	on	the	next	day.	Oral	
antibiotics	were	prescribed	for	7	days.	Patients	were	monitered	in	the	
outpatient	clinic	2	weeks	later.	During	each	follow-up	visit,	data	from	each	of	
the	GRA,	diary,	OSS,	ICPI,	ICSI,	Pain	VAS	were	recored.	Repeat	injections	were	
repeated	6	months	after	the	first	treatment,	and	patients	were	followed	up	in	
the	same	way.	The	BoNT-A	injection	was	repeated	every	6		months	until	
patients	felt	that	the	treatment	was	successful	up	to	4	injections.	
81	consecutive	patients	with	IC/BPS	who	had	experienced	conventional	treatment	failure	were	
prospectively	enrolled	from	July	2006	-	August	2010.	Diagnosis	was	established	based	on	
characteristic	symptoms	and	cytoscopic	findings	of	glomerulations,	petechia,	mucosal	fissue,	or	
ulceration.	All	patients	had	been	treated	with	at	least	one	of	the	following	medications:	oral	
pentosanpolysulphate,	intravesical	instillation	of	heparin,	hyaluronic	acid,	or	icyclic	antidepressant	
for	more	than	one	year	but	the	symptoms	remained	unchanged	or	had	relapsed.	They	were	
investigated	thoroughly	on	enrollment.	
81	patients	(71	
women,	and	10	men)	
OSS,	including	ICSI	and	ICPI.	VAS.	Video-
urodynamic	studies	at	baseline	and	end-
point.	Cystometric	studies.	GRA.	
OVerall,	the	GRA	and	symptom	variables	showed	
persistent	improvement	with	each	repeated	treatment	
when	baeline	of	each	successie	treatment	was	compared	
with	the	initial	study	baseline	level.
Among	81	patients,	20	received	single	injections,	19	
received	2	injections,	12	received	3	injections	and	30	
received	4	injections.	The	mean	sd	of	ICSI,	ICPI,	total	
scores,	VAS,	FBC,	and	daytime	frequency	all	showed	
significant	improvement	after	repeated	BoNT-A	treatment	
withd	ifferent	injections.	Significantly	better	success	rates	
were	noted	in	patients	who	received	4	repaeated	
injections	(p=0.0242)	and	3	injections	(P=0.05),	compared	
to	those	who	received	a	single	injection.	However,	there	
was	no	significant	difference	of	long-term	success	rates	
among	patients	who	received	2,	3,	and	4	injections.	
Chung	SD	(2012)
Taiwan
Prospective	non-
randomized	study
67	patients	with	IC/PBS	who	had	failed	conventional	treatments	were	
prospectively	enrolled	from	July	2007	to	August	2010.		atients	were	requested	
to	keep	a	bladder	diary	to	asses	frequency	and	nocturia.	Baseline	scores	were	
assessed	for	O'Leary	Sant	questionnaires	and	the	VAS	responses.	Video-
urodynamic	studies	and	pottasium	chloride	sensitivity	tests	were	preformed.	
Patients	with	GRA	>2	result	after	treatment	were	considered	to	have	a	
successful	treatment	outcome.	Patients	were	admitted	to	the	hospital	for	
treatment	where	they	received	intravesical	injection	of	botox,	followed	by	
cytoscopic	hydrodistention.	After	BoNT-A	injections,	a	catheter	remained	for	1	
day	and	patients	were	discharged	on	the	next	day.	Oral	antibiotics	were	
prescribed	for	7	days.	Patients	were	monitered	in	the	outpatient	clinic	2	
weeks	later.	During	each	follow-up	visit,	data	from	each	of	the	GRA,	diary,	
OSS,	ICPI,	ICSI,	Pain	VAS	were	recored.	Followup	was	recorded	at	3	months	
and	at	6	months	post	injection.
81	consecutive	patients	with	IC/BPS	who	had	experienced	conventional	treatment	failure	were	
prospectively	enrolled.	Diagnosis	was	established	based	on	characteristic	symptoms	and	
cytoscopic	findings	of	glomerulations,	petechia,	mucosal	fissue,	or	ulceration.	All	patients	had	
been	treated	with	at	least	one	of	the	following	medications:	oral	pentosanpolysulphate,	
intravesical	instillation	of	heparin,	hyaluronic	acid,	or	icyclic	antidepressant	for	more	than	one	year	
but	the	symptoms	remained	unchanged	or	had	relapsed.	They	were	investigated	thoroughly	on	
enrollment.	
67	patients	(60	women	
and	7	men)
OSS,	including	ICSI	and	ICPI.	VAS.	Video-
urodynamic	studies	at	baseline	and	end-
point.	Cystometric	studies.	GRA.	
Significant	improvement	was	shown	after	injection	
compared	to	baseline.	ICSI	(p=0.000),	ICPI	(p-0.000),	
VAS(p=0.000),	functional	bladder	capacity	(p=0.000),	GRA	
(p=0.000)
Giannantoni	A	(2010)
Italy
Prospective,	non-
randomized	study.
Patients	received	one	injection	of	BoNT/A	under	cystoscopic	guidance.	At	pre-	
and	3	months	post	treatment,	all	patients	underwent	an	urological	
assessment	(voiding	diary,	urodynamics),	a	pain	quanitification	on	VAS,	and	
evaluation	with	the	Hamilton	Anxiety	and	Hamilty	Depression	rating	scale,	and	
the	QoL	form.	
Refractory	pain	in	the	bladder	and	urethra,	vagina,	or	prineum	during	bladder	filling	or	after	
micturition;	frequency,	urgency	and	nocturia;	sterile	urine,	failure	of	all	previous	treatments	
including	oral	and	intravesical	therapies.	
12	patients	(all	
women)
VAS,	QoL,	HAM-A,	HAM-D,	Bladder	Diary Mean	VAS	score,	mean	daytime	and	nighttime	urinary	
frequency	all	decreased	significantly	(p<.01,	p<.01,	p<.01).	
All	domains	in	QoL	and	HAM-A	significantly	improved	
(p<.01,	p<.01).	All	domains	except	weight	and	sleep	
disoreders	significantly	improved	in	HAM-D	(p<.01)
Giannantoni	A	(2008)
Italy
Prospective,	
longitudinal	study
Under	short	general	anesthesia,	patients	were	given	injections	submucosally	
in	the	bladder	trigone	and	lateral	walls	under	cystoscopic	guidance.	A	voiding	
chart	and	the	visual	analog	scale	for	pain	were	used,	and	urodynamics	were	
performed	before	treatment	and	1,3,5,	and	12	months	later.	
Patients	with	refractory	pain	in	the	bladder	and	urethra,	vagina	or	perineum	durig	bladder	filling	or	
after	micturition	who	also	complained	of	frequency,	urgency,	and	nocturia.	All	previous	treaments,	
including	oral	and	intravesical	therapies,	had	failed	in	all	patients.
12	females	and	3	males.	Clinical	Evaluation,	VAS,	Cystoscopy	and	
urodynamics.	Local	and/or	systemic	side	
effects	were	noted.
Significant	improvements	in	daytime	and	night	time	
frequency	(p<.01,	p<.05)	VAS	(p<.01),	urodynamic	
parameters	(p<.01),	and	mean	maximum	cystometric	
capacity	(p<.01)	at	1	month	and	at	3	month.	
Bladder	pain	recurred	in	11	cases,	and	mean	VAS	score	
increased.	
At	1	year	-	bladder	pain	recurred	in	all	cases.	Clinical	and	
urodynamic	parameters	did	not	differ	with	respect	to	
those	at	baseline.	
Overall,	the	study	shows	significant	pain	relief	at	3	
months	in	86%	of	patients.	The	beneficial	effect	lasted	5	
months	in	about	30%	of	cases,	but	the	1-year	follow-up,	
pain	had	recurred	in	all.	
Smith	CP	(2004)
United	States/Poland
Prospective	
interventional	study
Patients	with	IC	under	short	general	anesthesia	or	sedation	were	injected	with	
Botulinum	toxin	through	a	cytoscope	submucosally	in	the	trigone	floor	of	the	
bladder.	Patients	were	evaluated	with	the	O'Leary-Sant	validated	IC	
questionnaire	or	with	voiding	charts	and	a	visual	analog	pain	scale	1	month	
postoperatively	and	at	subsequent	3	month	intervals.	Polish	patients	also	
underwent	pretreatment	and	post-treatment	urodynamic	evaluations
IC	was	diagnosed	according	to	the	NIDDK.	Previous	treatment	modalities,	including	oral	and	
intravesical	treatments	had	failed.	
12	females	-	6	in	US,	6	in	PolandICSI	 	ICPI,	VAS	
Urodynamic	parameters	were	assessed	in	
polish	patients
Overall,	9	(69%)	of	13	patients	noted	subjective	
improvement	after	BTX-A	treatment.	The	ICSI	and	ICPI	
mean	scores	improved	by	71%	and	69%	respectively	
(p<.05,	p<.05).	Daytime	frequency,	nocturia,	and	pain	by	
VAS	decreased	by	44$,	45%	and	79%	(P<0.01).	The	first	
desire	to	void	and	maximal	cystometric	capacity	increased	
by	58%	and	57%	respectively	(p<0.01).	
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